
AHR Stock Forecast & Price Target
AHR Analyst Ratings
Bulls say
American Healthcare REIT is favored because its RIDEA-heavy portfolio, led by Trilogy and traditional SHOP, is delivering strong organic growth from occupancy gains, pricing power, and margin expansion, with ISHC and SHOP representing about 60% and 22% of NOI as of 2Q26. It is also benefiting from an active acquisition program, with $1.4 billion completed YTD, an additional ~$1.3 billion awarded pipeline, and large investments expected to be accretive at high-5% to low-6% initial yields while supported by strong pre-funded equity. With net debt-to-EBITDA at 1.6x post transactions and an estimated 100-150 bps investment spread, the balance sheet appears flexible enough to sustain external growth and drive elevated AFFO growth through 2028.
Bears say
American Healthcare REIT is viewed negatively because its cash flows are unusually concentrated in Trilogy, which generated about 42% of 2024 NOI, while roughly 24% of total NOI comes from SNF operational cash flows that are more volatile and heavily dependent on government reimbursement. The thesis is further pressured by the risk of Medicaid cuts or the repeal of Indiana’s IGT add-on rates, which could lower Trilogy’s Medicaid rates, slow the investment pace, and trim the 7-YR AFFO CAGR by 500 bps to 10%+. As a result, the REIT faces heightened operational and regulatory risk, limited upside, and greater sensitivity to labor, reimbursement, and transparency around headwinds.
This aggregate rating is based on analysts' research of American Healthcare REIT Inc and is not a guaranteed prediction by Public.com or investment advice.
AHR Analyst Forecast & Price Prediction
Start investing in AHR
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About American Healthcare REIT Inc (AHR) Forecast
AHR Analyst Forecast & Price Prediction
Start investing in AHR
Order type
Buy in
Order amount
Est. shares
0 shares